AR064137A1 - Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe - Google Patents
Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfeInfo
- Publication number
- AR064137A1 AR064137A1 ARP070105428A ARP070105428A AR064137A1 AR 064137 A1 AR064137 A1 AR 064137A1 AR P070105428 A ARP070105428 A AR P070105428A AR P070105428 A ARP070105428 A AR P070105428A AR 064137 A1 AR064137 A1 AR 064137A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halo
- halogen
- optionally substituted
- Prior art date
Links
- -1 METHOD OF OBTAINING Substances 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title 1
- 230000003001 depressive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 11
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula general (1) en la que X e Y se eligen entre las combinaciones de: X es NR7 e Y es C=O, X es CH2, e Y es C=O, X-Y es N=N, o X es O e Y es C=O; R1 es hidrogeno, alquilo C1-6, opcionalmente sustituido por CN u OH, o -(alquileno C1-6)-C(O)-NRaRb, R2 es hidrogeno, alquilo C1-6, alcoxi C1-6, -(alquileno C1-6)-NRcRd, -(alquileno C1-6)-C(O)Rf, bencilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, o fenilo, opcionalmente sustituido por uno o más halogeno, haloalquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; R3 es H, halogeno, o alquilo C1-6; R4 es H, halogeno, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, o -O-alquenilo C2-10; R5 es H, halogeno, alquilo C1-6, o alcoxi C1-6, o R4 y R5 están unidos con el resto benzo para formar un anillo, en el que -R4-R5 es -O-(CH2)n-O-, en el que n es el numero 1 o 2; R6 es H, alquilo C1-6, opcionalmente sustituido por CN u OH, -(alquileno C1-6)-NRgRh, -(alquileno C1-6)-C(O)-NRiRj, -O-bencilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, nitro, halogeno, ciano, alcoxi C1-6, halo-alcoxi C1-6, halo-alquilo C1-6, -(alquileno C1-6)-C(O)Rf, fenilo, opcionalmente sustituido por halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, -(alquileno C1-3)-Rm, en el que Rm es fenilo, un heteroarilo de 5 o 6 eslabones, un heterocicloalquilo de 4 a 6 eslabones o un cicloalquilo de 3 a 6 eslabones, cada uno de ellos está opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; o R5 y R6 están unidos con el resto benzo para formar un anillo, en el que -R5-R6- es -O-(CH2)n-O-, -C(O)-(CH2)n-O-, o -O-(CH2)n-O-, en los que n es el numero 1 o 2; R7 es H o alquilo C1-6; R8, R9, R10, y R11 con independencia entre sí son H, halogeno, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6 o halo-alcoxi C1-6; Ra, Rb, Ri y Rj con independencia entre sí son: H, alquilo C1-6, -(alquileno C1-6)-NRkRl, en el que Rk y Rl con independencia entre sí son H o alquilo C1-6; o Ra y Rb, o Ri y Rj junto con el átomo de N al que están unidos forman un heterociclo de 5 o 6 eslabones que contiene uno o dos heteroátomos elegidos entre el grupo formado por N, O y S; Rc, Rd, Rg y Rh con independencia entre sí son: hidrogeno, alquilo C1-6, -C(O)Re, o -S(O)2Re, en los que Re se elige entre hidrogeno, alquilo C1-6, y fenilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; o Rc y Rd, o Rg y Rh junto con el átomo de nitrogeno al que están unidos forman un heterociclo de cinco o seis eslabones que contiene uno o dos heteroátomos elegidos entre el grupo formado por nitrogeno, oxígeno y azufre; o Rc y Rd, o Rg y Rh junto con el átomo de nitrogeno al que están unidos forman una isoindol-1,3-diona; Rf se elige entre el grupo formado por: hidrogeno, alquilo C1-6, alcoxi C1-6 y fenilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1- 6, halo-alcoxi C1-6, nitro, o ciano; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125663 | 2006-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064137A1 true AR064137A1 (es) | 2009-03-18 |
Family
ID=38983746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105428A AR064137A1 (es) | 2006-12-08 | 2007-12-05 | Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20080139618A1 (es) |
| EP (1) | EP2089381B1 (es) |
| JP (1) | JP2010511660A (es) |
| KR (1) | KR101050558B1 (es) |
| CN (1) | CN101541786A (es) |
| AR (1) | AR064137A1 (es) |
| AT (1) | ATE472544T1 (es) |
| AU (1) | AU2007328994B2 (es) |
| BR (1) | BRPI0720441A2 (es) |
| CA (1) | CA2671324A1 (es) |
| CL (1) | CL2007003503A1 (es) |
| DE (1) | DE602007007512D1 (es) |
| ES (1) | ES2345132T3 (es) |
| IL (1) | IL198683A0 (es) |
| MX (1) | MX2009005541A (es) |
| NO (1) | NO20091832L (es) |
| PE (1) | PE20081380A1 (es) |
| RU (1) | RU2009120443A (es) |
| TW (1) | TW200829570A (es) |
| WO (1) | WO2008068184A1 (es) |
| ZA (1) | ZA200903499B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101541786A (zh) * | 2006-12-08 | 2009-09-23 | 弗·哈夫曼-拉罗切有限公司 | 作为V1a受体拮抗剂的吲哚类化合物 |
| EP2102186B1 (en) * | 2006-12-08 | 2011-10-05 | F. Hoffmann-La Roche AG | Indoles |
| PE20081401A1 (es) * | 2006-12-28 | 2008-10-24 | Hoffmann La Roche | Derivados de indol como antagonistas de receptores vasopresina |
| EP2199967A1 (en) * | 2008-12-08 | 2010-06-23 | Electronics and Telecommunications Research Institute | Apparatus for providing digital contents using dmb channel and method thereof |
| JP2016513112A (ja) * | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| GB201521059D0 (en) * | 2015-11-30 | 2016-01-13 | Isis Innovation | Inhibitors of metallo-beta-lactamases |
| WO2020216378A1 (zh) * | 2019-04-26 | 2020-10-29 | 健艾仕生物医药有限公司 | 一种含杂环的化合物、其应用及含其的组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5924990B2 (ja) * | 1979-11-21 | 1984-06-13 | 協和醗酵工業株式会社 | 新規なピペリジン誘導体 |
| TW199153B (es) * | 1990-08-07 | 1993-02-01 | Dtsuka Seiyaku Kk | |
| EP0714299B1 (en) * | 1993-07-16 | 2002-04-24 | Merck & Co. Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| CO5150201A1 (es) | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | Derivados de piperidina |
| CZ301464B6 (cs) | 2000-05-12 | 2010-03-10 | Solvay Pharmaceuticals B. V. | Piperazinové a piperidinové slouceniny, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují |
| JP2006505570A (ja) | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
| PL1904477T3 (pl) * | 2005-07-14 | 2009-07-31 | Hoffmann La Roche | Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a |
| CA2616063A1 (en) * | 2005-07-21 | 2007-01-25 | F. Hoffmann-La Roche Ag | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists |
| ATE488519T1 (de) * | 2005-09-28 | 2010-12-15 | Hoffmann La Roche | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten |
| CN101541786A (zh) * | 2006-12-08 | 2009-09-23 | 弗·哈夫曼-拉罗切有限公司 | 作为V1a受体拮抗剂的吲哚类化合物 |
-
2007
- 2007-11-29 CN CNA2007800421348A patent/CN101541786A/zh active Pending
- 2007-11-29 WO PCT/EP2007/062984 patent/WO2008068184A1/en not_active Ceased
- 2007-11-29 ES ES07847501T patent/ES2345132T3/es active Active
- 2007-11-29 DE DE602007007512T patent/DE602007007512D1/de active Active
- 2007-11-29 MX MX2009005541A patent/MX2009005541A/es active IP Right Grant
- 2007-11-29 JP JP2009539706A patent/JP2010511660A/ja active Pending
- 2007-11-29 AT AT07847501T patent/ATE472544T1/de active
- 2007-11-29 CA CA002671324A patent/CA2671324A1/en not_active Abandoned
- 2007-11-29 KR KR1020097011629A patent/KR101050558B1/ko not_active Expired - Fee Related
- 2007-11-29 US US11/947,195 patent/US20080139618A1/en not_active Abandoned
- 2007-11-29 US US11/947,266 patent/US20080139617A1/en not_active Abandoned
- 2007-11-29 US US11/947,146 patent/US8071622B2/en not_active Expired - Fee Related
- 2007-11-29 AU AU2007328994A patent/AU2007328994B2/en not_active Ceased
- 2007-11-29 BR BRPI0720441-8A patent/BRPI0720441A2/pt not_active IP Right Cessation
- 2007-11-29 EP EP07847501A patent/EP2089381B1/en not_active Not-in-force
- 2007-11-29 US US11/998,371 patent/US7799923B2/en not_active Expired - Fee Related
- 2007-11-29 RU RU2009120443/04A patent/RU2009120443A/ru not_active Application Discontinuation
- 2007-12-05 CL CL200703503A patent/CL2007003503A1/es unknown
- 2007-12-05 AR ARP070105428A patent/AR064137A1/es unknown
- 2007-12-06 TW TW096146544A patent/TW200829570A/zh unknown
- 2007-12-07 PE PE2007001745A patent/PE20081380A1/es not_active Application Discontinuation
-
2009
- 2009-05-11 NO NO20091832A patent/NO20091832L/no not_active Application Discontinuation
- 2009-05-11 IL IL198683A patent/IL198683A0/en unknown
- 2009-05-20 ZA ZA200903499A patent/ZA200903499B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007328994A1 (en) | 2008-06-12 |
| PE20081380A1 (es) | 2008-09-18 |
| ZA200903499B (en) | 2010-03-31 |
| JP2010511660A (ja) | 2010-04-15 |
| KR101050558B1 (ko) | 2011-07-19 |
| BRPI0720441A2 (pt) | 2014-01-07 |
| TW200829570A (en) | 2008-07-16 |
| NO20091832L (no) | 2009-07-07 |
| KR20090078368A (ko) | 2009-07-17 |
| AU2007328994B2 (en) | 2012-03-08 |
| IL198683A0 (en) | 2010-02-17 |
| DE602007007512D1 (de) | 2010-08-12 |
| CA2671324A1 (en) | 2008-06-12 |
| ES2345132T3 (es) | 2010-09-15 |
| CL2007003503A1 (es) | 2008-07-04 |
| US20080139618A1 (en) | 2008-06-12 |
| ATE472544T1 (de) | 2010-07-15 |
| US20080139548A1 (en) | 2008-06-12 |
| US20080269290A1 (en) | 2008-10-30 |
| EP2089381A1 (en) | 2009-08-19 |
| US7799923B2 (en) | 2010-09-21 |
| RU2009120443A (ru) | 2011-01-20 |
| WO2008068184A1 (en) | 2008-06-12 |
| MX2009005541A (es) | 2009-06-05 |
| US20080139617A1 (en) | 2008-06-12 |
| CN101541786A (zh) | 2009-09-23 |
| US8071622B2 (en) | 2011-12-06 |
| EP2089381B1 (en) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064137A1 (es) | Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe | |
| AR064136A1 (es) | Derivados de espiro-piperidina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas con la accion antagonista del receptor v1a. | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR064138A1 (es) | Derivados de indol-2-il-carbonil-piperidina, antagonistas de receptores de vasopresina v1a, metodo de obtencion, composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios, depresivos y otras enfermedades. | |
| AR004972A1 (es) | Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado. | |
| AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR054327A1 (es) | Fenil-metanonas sustituidas por heterociclos, procesos de preparacion y composiciones farmaceuticas que lo contienen | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR032621A1 (es) | Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| ES2354569T3 (es) | Antagonistas del receptor de histamina-3. | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| AR047848A1 (es) | Analogos de rifamicina y composiciones farmaceuticas que los contienen. | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR067991A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptores de nk3 | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR064135A1 (es) | Derivados de espiro -piperidina | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
| AR064480A1 (es) | Derivados de espiro-piperidina | |
| AR051334A1 (es) | Derivados de 2- amido-4-feniltiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |